Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/29/2025

Treatment for UTI with Pseudomonas and VRE

VRE-Specific Treatment Approach

  • For uncomplicated urinary tract infections due to VRE, the American College of Physicians recommends fosfomycin as a single 3g oral dose, which has demonstrated promising results in retrospective observational studies and shows synergistic or additive effects when combined with other agents 1, 2, 3
  • Nitrofurantoin 100mg PO every 6 hours is an alternative first-line option for lower urinary tract VRE infections, with good in vitro activity against VRE and FDA approval since the 1950s for lower UTI treatment 2, 3, 4
  • High-dose ampicillin (18-30g IV daily) or amoxicillin (500mg IV/PO every 8 hours) can achieve sufficient urinary concentrations to overcome ampicillin resistance in VRE UTIs, with clinical and microbiological eradication rates of 88.1% and 86%, respectively, in patients with ampicillin-resistant VRE UTIs treated with ampicillin 2, 3, 5
  • For complicated VRE infections or bacteremia, linezolid 600mg IV or PO every 12 hours is strongly recommended, with treatment duration depending on infection site and clinical response 1
  • High-dose daptomycin (8-12 mg/kg IV daily) or in combination with β-lactams is recommended for VRE bacteremia, with a prospective observational study showing that high-dose daptomycin combined with β-lactams significantly reduced mortality compared to monotherapy 1, 3

Pseudomonas-Specific Treatment Approach

  • For complicated UTIs caused by carbapenem-resistant Enterobacteriaceae, ceftazidime-avibactam 2.5g IV every 8 hours is recommended, with alternative newer agents including meropenem-vaborbactam 4g IV every 8 hours or imipenem-cilastatin-relebactam 1.25g IV every 6 hours 1
  • Single-dose aminoglycoside is recommended for simple cystitis due to resistant organisms and as an alternative for complicated UTIs, minimizing toxicity while maintaining efficacy for lower tract infections 1

Critical Clinical Considerations

  • It is essential to differentiate colonization from true infection before prescribing anti-VRE antimicrobial agents, to prevent unnecessary antibiotic exposure and preserve treatment options 2, 5
  • Do not use tigecycline for VRE bacteremia due to large volume of distribution and low serum levels, despite its activity against VRE, and reserve it for intra-abdominal infections 1, 2, 3, 5
  • Infectious disease consultation is highly recommended for management of infections caused by multidrug-resistant organisms 1